Pain Management Olivier Cuignet, MD (responsible) Gregory Minguet, MD Jan Muller, MD Kirsten...

20
Pain Management Olivier Cuignet, MD (responsible) Gregory Minguet, MD Jan Muller, MD Kirsten Colpaert, MD

Transcript of Pain Management Olivier Cuignet, MD (responsible) Gregory Minguet, MD Jan Muller, MD Kirsten...

Page 1: Pain Management Olivier Cuignet, MD (responsible) Gregory Minguet, MD Jan Muller, MD Kirsten Colpaert, MD.

Pain ManagementPain Management

Olivier Cuignet, MD (responsible)Gregory Minguet, MD

Jan Muller, MDKirsten Colpaert, MD

Page 2: Pain Management Olivier Cuignet, MD (responsible) Gregory Minguet, MD Jan Muller, MD Kirsten Colpaert, MD.

pre-hospital care (su)fenta or piritramide iv

Treat as fast and as strong as possible to avoid mechanisms to be discussed

What kind of Burn patients ?

Opioids and FLUID CREEPBurns 2004; 30(6):583-90.

Page 3: Pain Management Olivier Cuignet, MD (responsible) Gregory Minguet, MD Jan Muller, MD Kirsten Colpaert, MD.

Pre-hospital care of burn patient

(su)fenta or piritramide iv(su)fenta or piritramide iv

Treat as fast and as strong as possible to Treat as fast and as strong as possible to avoid mechanisms to be discussedavoid mechanisms to be discussed

Opioids and FLUID CREEPLocal cooling and water gel

Treat the pain fast and strong with the minimum opioids needed :

« Cocktail de Djibouti » (Ketamine / Bzd / Atropine iv)

What kind of Burn patients ?

Page 4: Pain Management Olivier Cuignet, MD (responsible) Gregory Minguet, MD Jan Muller, MD Kirsten Colpaert, MD.

Aims Aims

Pain characteristics and analgesics

Lessons learned from our 6 years experience

New approach of burn pain nociceptive hyperalgesia

opioid-induced hyperalgesia

New strategy based on a new pain assessment

Page 5: Pain Management Olivier Cuignet, MD (responsible) Gregory Minguet, MD Jan Muller, MD Kirsten Colpaert, MD.

Pain CharacteristicsPain Characteristicsdressing changes, post-operative periods, physiotherapynursing care

Procedural Pain (PP): repetitivefrequentexcrutiating

Burn

Background Pain (BgP): constant breakthrough painexcruciating soundeasily defined diffuseresponds well to therapeutics increased therapeutic needs

Wind-ups: Complicated Pain (CP)

Page 6: Pain Management Olivier Cuignet, MD (responsible) Gregory Minguet, MD Jan Muller, MD Kirsten Colpaert, MD.

Pain control strategy : WHO Scale

Pain control strategy : WHO Scale

STEP 1 : Paracetamol ?

NSAID (Taradyl/Brufen) “10 mg”

STEP 2 : Tramadol 10 mg

Codeine 6.6 mg

STEP 3 : Piritramide 1.25 mg

Hydromorphone 0.134 mg

Morphine 1 mg

Sufentanyl 0.001 mg

Page 7: Pain Management Olivier Cuignet, MD (responsible) Gregory Minguet, MD Jan Muller, MD Kirsten Colpaert, MD.

Lessons learned from 6 years of Pain Management...

Lessons learned from 6 years of Pain Management...

Pain assessment is mandatory to meet patient’s need.

Appropriate Burn Pain therapy requires huge doses of morphine equivalent

Page 8: Pain Management Olivier Cuignet, MD (responsible) Gregory Minguet, MD Jan Muller, MD Kirsten Colpaert, MD.

Huge doses Opioids : burns are very painful

burn pain is a long-term process

burn pain is more and more painful

opioid become less efficient over time

Burn Pain therapyBurn Pain therapy

Page 9: Pain Management Olivier Cuignet, MD (responsible) Gregory Minguet, MD Jan Muller, MD Kirsten Colpaert, MD.

Background PainBackground Pain

Huge doses morphine-equivalent:Intensive Care : iv 100 à 168 mg/24h (sufenta) + bath

Medium Care : oral 65 à 200 mg /24h (tramadol + MSDirect +/- hydromorphone)

Potential problems:Fluid creep Burns 2004; 30(6):583-90.

Immunological Am J Ther 2004; 11(5):354-65.

Endocrine J Clin Endocrinol Metab 2000; 85(6):2215-22.

Tolerance Anasthesiol Intensivmed 2003; 38(1):14-26.

Hyperalgesia J Neurobiol 2004; 6(1):126-48.

Page 10: Pain Management Olivier Cuignet, MD (responsible) Gregory Minguet, MD Jan Muller, MD Kirsten Colpaert, MD.

Background PainBackground Pain

How to reduce high doses of morphine-equivalent?

Avoid the early hyperalgesia due to

burn and its inflammatory response

Avoid opioid tolerance / opioid hyperalgesiaby limiting the initial opioid doses

New comprehensive physio-pathology

of burn pain

Page 11: Pain Management Olivier Cuignet, MD (responsible) Gregory Minguet, MD Jan Muller, MD Kirsten Colpaert, MD.

Physio-pathology of burn pain.Physio-pathology of burn pain.

Three periods of Hyperalgesia:Activation (receptors recruitment)Modulation (NMDA, receptors

phosphorylation)Modification (new genes, apoptosis)

Three levels of Burn-induced Hyperalgesia:Peripheral (receptors/ nerves ending)Spinal (dorsal horn)Supra-spinal (brainstem, thalamus, cortex)

time

Non reversibility

Page 12: Pain Management Olivier Cuignet, MD (responsible) Gregory Minguet, MD Jan Muller, MD Kirsten Colpaert, MD.

Modified from O.H Wilder Smith. Anesthesiology 104, 2006; 601-7

Burn

Page 13: Pain Management Olivier Cuignet, MD (responsible) Gregory Minguet, MD Jan Muller, MD Kirsten Colpaert, MD.

Treat the pain as soon as possible(before activation of pain amplification mechanisms)

Treat the pain as completely as possibleat the periphery

at the spinal level

at the supra-spinal level

Physio-pathology of burn pain.Physio-pathology of burn pain.

Page 14: Pain Management Olivier Cuignet, MD (responsible) Gregory Minguet, MD Jan Muller, MD Kirsten Colpaert, MD.

Treat the pain as soon as possible(before pain amplification mechanisms activated)

Treat the pain as completely as possibleat the periphery

at the spinal levelat the supra-spinal level

Treat the pain with as few opioids as possibleto avoid opioid-induced hyperalgesia

to avoid opioid-tolerance

Physio-pathology of burn pain.Physio-pathology of burn pain.

Page 15: Pain Management Olivier Cuignet, MD (responsible) Gregory Minguet, MD Jan Muller, MD Kirsten Colpaert, MD.

Physio-pathology of burn pain.Physio-pathology of burn pain.

Modified from O.H Wilder Smith. Anesthesiology 104, 2006; 601-7

Page 16: Pain Management Olivier Cuignet, MD (responsible) Gregory Minguet, MD Jan Muller, MD Kirsten Colpaert, MD.

Pain Control StrategyPain Control Strategy

Peripheral hyperalgesiaHydro-colloids dressing, homografts, antiseptic ointments. Early excisionLoco-regional anesthesia

Page 17: Pain Management Olivier Cuignet, MD (responsible) Gregory Minguet, MD Jan Muller, MD Kirsten Colpaert, MD.

Procedural Pain: post-operativeProcedural Pain: post-operative

Post-operative:loco-regional anesthesia for donor sites

long-term opioid-sparing effects J Burn Care Rehabil. 2005 Sep-Oct;26(5):409-15

0

1

2

3

4

5

6

7

8

9

10

VA

S s

core

(Dyn

amic

)

6 h 24 h 48 h 72 h 1st Dressing change

controlblockcatheter

0

20

40

60

80

100

120

6 h 24 h 48 h 72 h

control

block

catheter

Post-operative time

Cum

ulat

ive

mor

phin

e (m

g)

Page 18: Pain Management Olivier Cuignet, MD (responsible) Gregory Minguet, MD Jan Muller, MD Kirsten Colpaert, MD.

Pain Control StrategyPain Control Strategy

Peripheral hyperalgesiaHydro-colloids dressing, homografts, antiseptic ointments. Early excisionLoco-regional anesthesia

Spinal and supraspinal hyperalgesiaAnti-hyperalgesic drugs : kétamine, lidocaine, pregabalinOpioid-sparing agent : clonidine

Page 19: Pain Management Olivier Cuignet, MD (responsible) Gregory Minguet, MD Jan Muller, MD Kirsten Colpaert, MD.

Pain Control StrategyPain Control Strategy

0

500

1000

1500

2000

2500

3000

Tre

atm

en

t Da

y 1

Tre

atm

en

t Da

y 2

Tre

atm

en

t Da

y 3

Tre

atm

en

t Da

y 4

Tre

atm

en

t Da

y 5

Tre

atm

en

t Da

y 6

Tre

atm

en

t Da

y 7

Tre

atm

en

t Da

y 8

Tre

atm

en

t Da

y 9

Tre

atm

en

t Da

y 1

0

Tre

atm

en

t Da

y 1

1

Tre

atm

en

t Da

y 1

2

Tre

atm

en

t Da

y 1

3

Tre

atm

en

t Da

y 1

4

Tre

atm

en

t Da

y 1

5

Tre

atm

en

t Da

y16

Tre

atm

en

t Da

y 1

7

Tre

atm

en

t Da

y 1

8

Tre

atm

en

t Da

y 1

9

Tre

atm

en

t Da

y 2

0

Tre

atm

en

t Da

y 2

1

ControlGabapentin

Cu

mu

lativ

e M

orp

hin

e c

on

sum

ptio

n (

mg

)

p < 0.05

0

500

1000

1500

2000

2500

3000

Po

stT

r D

ay

1

Po

stT

rDa

y 2

Po

stT

r D

ay

3

Po

stT

r D

ay

4

Po

stT

r D

ay

5

Po

stT

rDa

y 6

Po

stT

r D

ay

7

Po

stT

r D

ay

8

Po

stT

r D

ay

9

Po

stT

r D

ay

10

Po

stT

r D

ay

11

Po

stT

rDa

y 1

2

Po

stT

r D

ay

13

Po

stT

r D

ay

14

Po

stT

r D

ay

15

Po

stT

r D

ay1

6

Po

stT

r D

ay

17

Po

stT

r D

ay

18

Po

stT

r D

ay

19

Po

stT

r D

ay

20

Po

stT

r D

ay

21

ControlGabapentin

Cu

mu

lativ

e M

orp

hin

e c

on

sum

ptio

n (

mg

)

p < 0.05

Gabapentin reduces opioid-consumption during and up to 3 weeks after its administrationBurns. 2007 Feb;33(1):81-6

Page 20: Pain Management Olivier Cuignet, MD (responsible) Gregory Minguet, MD Jan Muller, MD Kirsten Colpaert, MD.

Pain Control StrategyPain Control Strategy

Peripheral hyperalgesiaHydro-colloids dressing, homografts, antiseptic ointments. Early excisionLoco-regional anesthesia

Spinal and supraspinal hyperalgesiaAnti-hyperalgesic drugs : kétamine, lidocaine, pregabalinOpioid-sparing agent : clonidine

Opioid-induced hyperalgesiaAssessment of hyperalgesia Judicious use of antihyperalgesic drugs (ketamine, lidocaine, pregabalin)Loco-regional anesthesia

To do